Overcoming the problem of chronic hepatitis B

Drug Discovery Today: Therapeutic Strategies

Volumn 3, Issue 2, 2006, Pages 197-202

  Fung, James ^a   Lai, Ching Lung ^a   Yuen, Man Fung ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 9 (1 PHOSPHONOMETHOXYCYCLOPROPYLMETHYL)PURINE BIS(PIVALOYLOXYMETHYL) ESTER; ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ANTIVIRUS AGENT; CLEVUDINE; CORE PROTEIN; CY 1899; DNA VACCINE; EMTRICITABINE; ENTECAVIR; HEPATITIS B VACCINE; IMMUNOMODULATING AGENT; INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; PEGINTERFERON; PEGINTERFERON ALPHA; RECOMBINANT INTERLEUKIN 2; TELBIVUDINE; TENOFOVIR DISOPROXIL; THYMOSIN ALPHA1; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS ENVELOPE PROTEIN; VIRUS RNA;

ANTIVIRAL ACTIVITY; CLINICAL PROTOCOL; CLINICAL TRIAL; DNA TRANSCRIPTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ERADICATION THERAPY; FLU LIKE SYNDROME; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; LIVER DYSFUNCTION; META ANALYSIS; MOOD DISORDER; NEPHROTOXICITY; NONHUMAN; REVIEW; RNA TRANSCRIPTION; RNA TRANSLATION; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 33746861983     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2006.05.001     Document Type: Review

References (40)

1. Ganem D., and Prince A. Hepatitis B virus infection-natural history and clinical consequences. N. Engl. J. Med. 350 (2004) 1118-1129
2. Guidotti L.G., and Chisari F.V. Cytokine-mediated control of viral infections. Virology 273 (2000) 221-227
3. Wong D., et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann. Intern. Med. 119 (1993) 312-323
4. Cooksley W., et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J. Viral Hepatol. 10 (2003) 298-305
5. Lau G., et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 352 (2005) 2682-2695
6. Marcellin P., et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 351 (2004) 1206-1217
7. Yuen M.F., et al. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 34 (2001) 139-145
8. Chan H., et al. The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis. Aliment Pharmacol. Ther. 15 (2001) 1899-1905
9. Artillo S., et al. Double-blind, randomized controlled trial of interleukin-2 treatment of chronic hepatitis B. J. Med. Virol. (1998) 54
10. Dahmen A., et al. Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B. J. Med. Virol. 66 (2002) 452-460
11. Pol S., et al. Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J. Hepatol. 34 (2001) 917-921
12. Heathcote J., et al. A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group. Hepatology 30 (1999) 531-536
13. Roy M., et al. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 19 (2000) 764-778
14. Lai C.L., et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N. Engl. J. Med. 339 (1998) 61-68
15. Dienstag J., et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. 341 (1999) 1256-1263
16. Liaw Y.F., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 351 (2004) 1521-1531
17. Lai C.L., et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin. Infect. Dis. 36 (2003) 687-696
18. Allen M., et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 27 (1998) 1670-1677
19. Marcellin P., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med. 348 (2003) 808-816
20. Hadziyannis S., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 352 (2005) 2673-2681
21. Perrillo R., et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 32 (2000) 129-134
22. Locarnini S. et al. (2005) Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB). 40th European Association for the Study of the Liver, 13-17 April 2005, Paris, France (Abstract 36)
23. Angus P., et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 125 (2003) 292-297
24. Lai C.L., et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 354 (2006) 1011-1020
25. Chang T.T., et al. A Comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 354 (2006) 1001-1010
26. Tenney D., et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob. Agents Chemother. 48 (2004) 3498-3507
27. van Bommel F., et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 40 (2004) 1421-1425
28. Lai C.L., et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 129 (2005) 528-536
29. Lai C.L. et al. (2005) Telbivudine (LdT) vs. lamivudine for chronic hepatitis B: first year results from the international phase III GLOBE trial. 56th American Association for the Study of Liver Diseases, 11-15 November 2005, San Francisco, CA, USA (Late Breaking Abstract 1)
30. Marcellin P., et al. A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. Hepatology 40 (2004) 140-148
31. Fu L., et al. Sensitivity of l-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues. Biochem. Pharmacol. 57 (1999) 1351-1359
32. Lim S.G., et al. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch. Intern. Med. 166 (2006) 49-56
33. Yuen M.F. et al. (2004) Phase I/II, double blind, randomized, placebo-controlled trial of the novel anti-HBV agent LB80380/ANA380 in patients with chronic HBV. 55th American Association for the Study of Liver Diseases, 29 October-2 November 2004, Boston, MA, USA (Abstract 172)
34. King R., et al. Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-)beta-L-2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. (1998) 41
35. Korba B., and Gerin J. Antisense oligonucleotides are effective inhibitors of hepatitis B virus replication in vitro. Antiviral Res. 28 (1995) 225-242
36. Zu Putlitz J., et al. Antisense RNA complementary to hepatitis B virus specifically inhibits viral replication. Gastroenterology 115 (1998) 702-713
37. Hoeprich S., et al. Bacterial virus phi29 pRNA as a hammerhead ribozyme escort to destroy hepatitis B virus. Gene. Ther. 10 (2003) 1258-1267
38. Robaczewska M., et al. Inhibition of hepadnaviral replication by polyethylenimine-based intravenous delivery of antisense phosphodiester oligodeoxynucleotides to the liver. Gene. Ther. 11 (2001) 874-881
39. Robaczewska M., et al. Sequence-specific inhibition of duck hepatitis B virus reverse transcription by peptide nucleic acids (PNA). J. Hepatol. 42 (2005) 180-187
40. Shlomai A., and Shaul Y. Inhibition of hepatitis B virus expression and replication by RNA interference. Hepatology 37 (2003) 764-770